je.st
news
Home
› X-Chem And Navitor Pharmaceuticals Enter Into License Agreement On Novel Small Molecules Targeting mTORC1 Activation
X-Chem And Navitor Pharmaceuticals Enter Into License Agreement On Novel Small Molecules Targeting mTORC1 Activation
2015-04-01 08:58:00| drugdiscoveryonline Home Page
X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, recently announced that Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, exercised its option to obtain an exclusive license to a series of small molecules targeting the activation of mTORC1, a key protein complex that orchestrates nutrient-mediated cellular metabolism and growth
Tags: enter
small
agreement
license
Category:Biotechnology and Pharmaceuticals